In order to test the effectiveness of tangeretin at ameliorating melanoma and melanoma-associated depigmentation, western blotting was used to assess the melanin content of treated melanoma cells. Tangeretin, a 4',5,6,7,8-pentamethoxyflavone, was found to trigger intracellular melanin production in a concentration-dependent manner in B16/F10 murine melanoma cells. Melanin content increased 1.74-fold in response to treatment with 25 μM of tangeretin, compared to that in non-treated cells. Examination of melanogenic protein expression showed that tyrosinase, tyrosinase-related protein (TRP)-1, and extracellular signal-regulated kinase (ERK) 1/2 levels increased in a dose-dependent manner. Furthermore, the expression of cyclic adenosine monophosphate response element binding protein (CREB) and microphthalmia transcription factor (MITF) was increased by tangeretin in 1 h and 4 h, respectively. Tangeretinupregulated melanogenesis was suppressed by ERK 1/2 inhibitor and not by ERK1 inhibitor. These results suggest that tangeretin has therapeutic potential for melanoma and melanoma-associated depigmentation because it can induce hyperpigmentation through the activation of melanogenic signaling proteins and initiation of sustained ERK2 expression.
Methoxylated flavones, in which the hydroxyl groups are capped with methyl groups, have been shown to be biologically and pharmaceutically active and regulate melanogenesis, differentiation, and other physiological processes. The methoxyflavones have been reported to dramatically enhance metabolic stability and membrane transport in the intestine and liver and, as a result, improve oral bioavailability [1] . Nobiletin, a 5,6,7,8,3',4'-hexamethoxyflavone, triggers melanogenesis and differentiation in B16/F10 melanoma cells and induces neuritogenesis in PC12D cells [2] [3] . Sinensetin, a 5,6,7,3',4'-pentamethoxyflavone, has an antiangiogenic effect in zebrafish, and inhibits carrageenan-induced paw inflammation in mice [4] [5] . Tangeretin, a 5,6,7,8,4'-pentamethoxyflavone ( Fig 1A) , suppresses a number of cellular activities including the growth of mammary cancer cells in vitro and cytolysis by natural killer (NK) cells in vivo [6] . Recently, there have been many reports on the induction of melanin production by methoxylated compounds, such as nobiletin, tangeretin, sinensetin, 4'-O-methylfisetin, 7-hydroxy-6methoxycoumarin, 7-methoxycoumarin, 6,7-dimethoxycoumarin, and 5,7-dimethoxycoumarin [7] [8] [9] , and there has also been a great deal of research into the stimulation of melanin synthesis using hydroxylated compounds, such as quercetin, naringenin, and isoliquiritigenin [10] [11] [12] . Recent reports have revealed that nobiletin stimulates melanogenesis via temporal extracellular signal-regulated kinase (ERK) inhibition and sustained ERK activation, and induces neuritogenesis via sustained ERK activation [13] . ERK has been shown to be activated in a sustained manner by different stimuli: nerve growth factor (NGF) in PC12D cells, brain-derived neurotrophic factor (BDNF) in the rat hippocampus, and alphamelanocyte-stimulating hormone (α-MSH) and nobiletin in B16 melanoma cells [14] [15] . Recent reports show that α-MSH-induced melanogenesis can be downregulated via suppression of sustained ERK activation using Petalonia binghamiae and lily bulb extracts obtained from marine and land plants [16] [17] . Other research shows that nobiletin-induced sustained ERK activation can be suppressed by the mitogen-activated protein kinase (MEK) 1/2 inhibitor, U0126 that inhibits phosphorylated ERK 1/2 [2] . Phosphorylated cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) interacts with CREB binding protein (CBP) to activate the expression of microphthalmiaassociated transcription factor (MITF). MITF is an essential factor involved in the regulation of the transcription of major melanogenic proteins including tyrosinase, tyrosinase-related protein-1 (TRP-1) and TRP-2 [18] [19] .
Melanin can be synthesized in two chemically distinct types: blackto-brown eumelanin and yellow-to-reddish brown pheomelanin. Eumelanin and pheomelanin are both derived from the common precursor dopaquinone (DQ), which is formed by the tyrosinasecatalyzed oxidation of the common amino acid L-tyrosine, which involves the transient intermediate L-3,4-dihydroxyphenylalanine (DOPA). Eumelanins are dark and highly polymerized while pheomelanins contain sulfur and are lighter and less polymerized [20] . Tyrosinase also exhibits many other enzymatic functions such as tyrosine hydroxylase, dihydroxyphenylalanine (DOPA) oxidase and 5,6-dihydroxyindole (DHI) oxidase activities. Although TRP-1 exhibits 5,6-dihydroxyindole carboxylic acid (DHICA) oxidase activity, its exact functions are not clear. It has also been suggested that TRP-1 stabilizes tyrosinase [21] . In addition, TRP-2 functions as a DOPAchrome tautomerase [22] . Melanogenic activators such as α-MSH have been reported to mediate the opposite effects in tyrosinase and TRP-2 in B16/F10 murine melanoma cells [23] . Research into the melanogenic effect of tangeretin in B16/F10 melanoma cells can be expected to increase the elementary understanding of its therapeutic potential for the treatment of melanoma and melanoma-associated depigmentation.
Tangeretin is a nonpeptidic, low-molecular-weight polymethoxyflavone obtained from citrus fruit, whereas α-MSH is a polypeptide that binds to melanocortin-1 receptor. Treatment of cells with 6-25 μM tangeretin did not result in any cytotoxicity based on the release of lactate dehydrogenase (LDH) but slightly decreased cell viability according to a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay ( Figure 1B ). Tangeretin triggered melanin production in a dose-dependent manner ( Figure 1C ). These results indicate that tangeretin affects melanoma cell differentiation and exerts an antiproliferative effect as has been previously shown for nobiletin [3] . Recent reports show that nobiletin stimulates neurite outgrowth in PC12D cells, increases intracellular cAMP, leads to sustained expression of mitogen-activated protein kinase (MAP), MEK, and ERK, and sustained cAMP response element (CRE)-mediated transcription, and triggers 3T3-L1 cell differentiation by activating ERK, CREB, and the accumulation of lipid droplets [24] [25] .
Melanogenesis is the differentiation marker of melanocytes and melanoma cells. Melanin production is regulated by melanogenic enzymes such as tyrosinase and TRP-1 and -2 [26] . Melanin is produced by the tyrosinase-mediated conversion of L-tyrosine into dopaquinone, which is the rate-limiting step of melanin production [27] . To estimate the contribution of melanogenic proteins to tangeretin-triggered melanogenesis, western blot analysis was performed. The expression levels of tyrosinase, TRP-1, and p-ERK 1/2 were found to increase following tangeretin treatment in a concentration-dependent manner (Figure 2A ). Increasing evidence indicates that the ERK signaling pathway plays a pivotal role in melanogenesis. UVA irradiation-induced melanogenesis is associated with ERK activation in melanocytes and is strongly involved in the sphingosine-1 phosphate (S1P)-induced melanogenic signaling cascade and cAMP-induced melanin biosynthesis [28] [29] [30] . Inhibition of the MAPK pathway triggers differentiation of melanoma cells and melanogenesis [31] .
Recent reports revealed that nobiletin-induced melanogenesis is associated with sustained ERK activation [2] . The most important transcription factor in the regulation of both tyrosinase and TRP-1 gene expression is MITF, which plays a pivotal role in the regulation of many aspects of melanocyte survival and differentiation [32] . To evaluate the mechanism by which tangeretin stimulates melanin production, B16/F10 melanoma cells were treated with 25 μM tangeretin for various lengths of time. It has been reported that the maximum protein expression of MITF is observed after 3-5 h of treatment with 6-benzylaminopurine and it then decreases after 24 h [33] . We found that MITF expression was significantly increased after 4 h of treatment with tangeretin. Phosphorylation of CREB binds the CRE consensus motif of the MITF-M promoter to upregulate MITF gene expression [36]; therefore, we evaluated the phosphorylation of CREB using western blot analysis. Incubation with 25 μM tangeretin for 0.5-1 h was found to increase the level of CREB phosphorylation ( Figure 2B ).
To clarify the relationship between melanin production and the sustained ERK activation that is triggered by tangeretin, we measured the changes in tangeretin-induced melanogenesis using SB203580 (p38 MAP kinase inhibitor), PD98059 (inhibitor of MEK 1), SB600125 (inhibitor of JNK), and U0126 (inhibitor of MEK 1/2). The results showed that only U0126 decreased tangeretin-stimulated melanin production ( Figure 3A ) and protein expression of tyrosinase, indicating that tangeretin increased melanin production through the ERK signaling pathwayspecifically the MEK 2 pathway -but not through the p38, JNK or MEK 1 pathways ( Figure 3B ). Tangeretin-stimulated ERK activation was suppressed by U0126, and subsequently tyrosinase was inhibited by U0126. Treatment with U0126 appeared to more effectively suppress tangeretin-stimulated ERK activation than treatment with PD98059.
These results showed that tangeretin upregulates tyrosinase expression through pathways involving sustained ERK activation and suggest that tangeretin can stimulate melanogenesis in murine B16/F10 melanoma cells. Furthermore, the ERK/MAPK signaling pathway, specifically the ERK2 signaling pathway, is essential for tangeretin-triggered pigmentation. In conclusion, these results suggest that tangeretin can be used as a therapeutic agent against melanoma and/or melanoma-associated depigmentation, and it functions via stimulation of the melanogenic signaling pathway through sustained ERK2 activation.
Experimental
Materials: All solvents were of analytical grade and used without any further purification. Tangeretin and α-MSH were purchased from Sigma Chemical Co. (St. Louis, MI, USA). U0126 (MEK1/2 inhibitor), PD98059 (MEK1 inhibitor), SB203580 (p38 inhibitor) and SB600125 (JNK inhibitor) were purchased from Cell Signaling Technologies (Danvers, MA, USA).
Cell culture: B16/F10 murine melanoma cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gibco), 1% penicillin-streptomycin (10, 000 U/mL and 10,000 μg/mL, Gibco). The cells were maintained in a humid atmosphere of 5% CO 2 at 37°C.
Cytotoxicity:
The cytotoxicity of tangeretin and α-MSH was determined using the LDH release assay. Leakage of LDH from cells following treatment is a well-known marker of damage to the cellular membrane and as a result cytotoxicity can be estimated by measuring LDH. Cytotoxicity was expressed as the percentage of LDH released into the culture supernatant (LDH release into medium following tangeretin or α-MSH treatment/maximal LDH release × 100). Maximal LDH release was measured after lysis of cells with 0.5% Triton X-100.
Cell viability:
The cell viability was determined using the MTT assay. Briefly, cells were seeded into 96-well plates at a density of 1×10 4 cells per well in the presence or absence of tangeretin or α-MSH. After two days incubation, the mitochondrial enzyme activity, which is an indirect measure of the number of viable respiring cells, was determined using the MTT reagent. Finally, the absorbance was measured at 540 nm and the effect of tangeretin or α-MSH on cell viability was evaluated relative to an untreated control.
Intracellular melanin content: B16/F10 murine melanoma cells were seeded into 6-well plates at a density of 1×10 5 cells per well. The cells were then treated with or without the test compounds at 37°C for 2 days. Next, the cells were washed with 1× PBS and then collected in 1× trypsin-EDTA, after which they were lysed with 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and 1% Triton X-100 in 67 mM sodium phosphate buffer (pH 6.8). The samples were then sonicated and centrifuged at 15,000 rpm for 15 min at 4°C. To extract the melanin from the pellets, 1 N NaOH was added to the pellets and subsequently incubated at 70°C for 4 h. The absorbance was then measured at 405 nm and the corresponding total protein was used to normalize the absorbance.
Western blot analysis:
Phosphorylated ERK 1/2, tyrosinase, TRP-1, TRP-2 and MITF were purchased from Santa Cruz Biotech. Phosphorylated CREB and CREB were obtained from Cell Signaling and β-actin from Sigma Chemical Co. (St. Louis, USA). Cells were collected and lysed in 1× RIPA buffer, 0.1 mM PMSF, 0.1 M Na 3 VO 4 , 0.5 M NaF, 5 mg/mL aportinin, and 5 mg/mL leupeptin). Thirty micrograms of protein was used per lane and was separated using SDS-PAGE and subsequently blotted onto nitrocellulose membranes. The nitrocellulose membranes were then blocked with 5% dried milk in Tris-buffered saline containing 0.05% Tween 20. Next, the blots were incubated with primary antibodies at a dilution of 1:1,000 and then further incubated with horseradish peroxidase-conjugated secondary antibody. The bound antibodies were then detected using an enhanced chemiluminescence kit (GE Healthcare Life Sciences, UK).
MAP Kinase Inhibitor Assay:
B16/F10 murine melanoma cells were seeded at a density of 1×10 5 cells/well into 6-well plates. After 24 h incubation, they were treated with 5 µM U0126, 5 µM PD98059, 5 µM SB203580 or 2.5 µM SB600125. Then, the cells were treated with 25 µM tangeretin after 30 min. Subsequently, the cells were incubated for 48 h. To confirm the specific MAP kinase pathway involved in tangeretin-induced melanogenesis, melanin content was determined using western blotting to assess the expression of tyrosinase.
Statistical Analysis:
All experiments were performed in triplicate. Treatment effects were analyzed using the Student's t-test; p < 0.05 was considered to be statistically significant.
